Published in Healthcare Finance, Tax and Law Weekly, August 22nd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Cytogen.
Report 1: Cytogen Corporation (NASDAQ: CYTO) today reported results from clinical trials demonstrating that QUADRAMET (samarium Sm-153 lexidronam injection) can be safely administered to prostate cancer patients who are also receiving the chemotherapy docetaxel (Taxotere(R), Sanofi-Aventis). Clinical data also support further evaluation of the combination regimen for the treatment of prostate cancer in a Phase 2 program. The results were presented and/or published at the 43rd Annual Meeting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.